Trevogrumab (REGN-1033)

Overview

Trevogrumab (REGN-1033) is a monoclonal antibody developed by Regeneron Pharmaceuticals that selectively binds and neutralizes GDF-8 (growth differentiation factor 8), more commonly known as myostatin. By targeting the primary endogenous inhibitor of skeletal muscle growth, Trevogrumab has been studied for its ability to increase muscle mass, reduce adipose tissue, and preserve lean body composition in the context of muscle-wasting diseases and obesity pharmacology. FenaLife supplies Trevogrumab for laboratory research use only.

Research Background

Trevogrumab has been evaluated in clinical research as a standalone agent and in combination with other compounds. Notably, Regeneron investigated a triple-combination approach pairing semaglutide, Trevogrumab, and garetosmab (an anti-activin A antibody) in a Phase 1 body composition study. Results from the American Diabetes Association (2024) reported that combined myostatin and activin A blockade, alongside GLP-1 receptor agonism, produced favorable shifts in lean mass versus fat mass — an area of active investigation as of 2026. The compound represents Regeneron’s effort to address muscle loss associated with GLP-1-driven weight reduction.

Studied Mechanisms

Trevogrumab binds the mature, active form of myostatin (GDF-8), preventing it from engaging ActRIIB receptors on muscle cells. This lifts the endogenous brake on skeletal muscle hypertrophy, shifting the anabolic/catabolic balance toward net muscle protein synthesis. Unlike broader ActRII blockers (such as Bemagromab), Trevogrumab is selective for myostatin, leaving other ActRIIB ligands (activin A, GDF-11) unaffected — a distinction that may influence its safety and tissue-specificity profile in research settings.

Molecular Profile

Type: Human monoclonal antibody (IgG4). Target: GDF-8 / Myostatin. Also known as: REGN-1033. Developer: Regeneron Pharmaceuticals. Molecular weight: ~148 kDa (typical IgG). Purity: ≥98% by HPLC.

Storage and Handling

Store lyophilized Trevogrumab at -20°C, protected from light and moisture. Reconstitute with sterile or bacteriostatic water as appropriate. Store reconstituted solution at 4°C and use within 4 to 6 weeks. Avoid repeated freeze-thaw cycles to maintain structural integrity.

Research Use Only

For laboratory research purposes only. Not for human or veterinary use. Certificate of Analysis available per batch.